A carregar...
Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment
AIMS: The aim of this study was to develop a population pharmacokinetic (PK) model of udenafil and its active metabolite, DA‐8164, in healthy subjects and patients with hepatic impairment (HI) and to estimate the optimal dosing recommendations for patients with HI. METHODS: An open label, three para...
Na minha lista:
| Publicado no: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4972155/ https://ncbi.nlm.nih.gov/pubmed/27084997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12977 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|